← 홈

림프종

587개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 587개
ADCBiologicstaleChinese Academy of Medical Scie…Preclinical

Maintenance therapy-chidamide (Maintenance therapy-chidamide)

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 30상태 RECRUITING
AntibodystaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#항체#면역항체+5
효능 ORR 25%임상시험 30상태 RECRUITING
ADCBiologicstaleFondazione Italiana Linfomi - E…Phase 2

R-DHAP (R-DHAP)

Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent · DLBCL

#DLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 51.4%임상시험 30상태 DISCONTINUED
ADCBiologicstaleCalithera Biosciences, IncPhase 2

Sapanisertib (Sapanisertib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 18.4%임상시험 30상태 RECRUITING
AntibodystaleTG Therapeutics, Inc.Phase 2

Ublituximab (Ublituximab)

Non-Hodgkins Lymphoma; B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 84.4%임상시험 30상태 ACTIVE
ADCBiologicstaleAmerican Society of Clinical On…Phase 2

Vemurafenib and Cobimetinib (Vemurafenib and Cobimetinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 65%임상시험 30상태 RECRUITING
CGTBiologicstaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 94%임상시험 30상태 RECRUITING
CGTBiologicstaleTakedaPhase 1

anti-CD19 CAR-NK (anti-CD19 CAR-NK)

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 0%임상시험 30상태 RECRUITING
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
ADCBiologicstaleAscentage Pharma Group Inc.Phase 2

Lisaftoclax (Lisaftoclax)

Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B Cell Lymphoma (DLBCL)

#DiffuseLargeBCellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 29상태 RECRUITING
ADCBiologicstaleAmgenPhase 3

calaspargase pegol (calaspargase pegol)

B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma · NK-Cell Lymphoma

#NK-CellLymphoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 28상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 71.7%임상시험 27상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 25상태 RECRUITING
ADCBiologicstaleNational Cancer Institute (NCI)vedotin, and venetoclax dem…Phase 2

Larotrectinib (Larotrectinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 94.4%임상시험 25상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

POLA-R-CHP (POLA-R-CHP)

Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 95%임상시험 25상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 24상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING
ADCBiologicstaleTaiho Oncology, Inc.Phase 2

Futibatinib (Futibatinib)

Advanced Solid Tumor · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 47.1%임상시험 23상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Nemtabrutinib (Nemtabrutinib)

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma; Gastric Mucosa-Associated Lymphoid Tissue Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0.0%임상시험 23상태 RECRUITING
ADCBiologicstaleCelgenePhase 2

CC-99282 (CC-99282)

Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 21상태 RECRUITING

7 / 30 페이지

← 이전다음 →